Analytical Data
-
Gene name
EIF4A3
- Application
-
Alternative Names
EIF4A3；MLN51;Protein CASC3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P38919
-
Expression Region
1-411aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSHMATTAT MATSGSARKR LLKEEDMTKV EFETSEEVDV TPTFDTMGLR EDLLRGIYAY GFEKPSAIQQ RAIKQIIKGR DVIAQSQSGT GKTATFSISV LQCLDIQVRE TQALILAPTR ELAVQIQKGL LALGDYMNVQ CHACIGGTNV GEDIRKLDYG QHVVAGTPGR VFDMIRRRSL RTRAIKMLVL DEADEMLNKG FKEQIYDVYR YLPPATQVVL ISATLPHEIL EMTNKFMTDP IRILVKRDEL TLEGIKQFFV AVEREEWKFD TLCDLYDTLT ITQAVIFCNT KRKVDWLTEK MREANFTVSS MHGDMPQKER ESIMKEFRSG ASRVLISTDV WARGLDVPQV SLIINYDLPN NRELYIHRIG RSGRYGRKGV AINFVKNDDI RILRDIEQYY STQIDEMPMN VADLI
-
Molecular Weight
49 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EIF4A3, a member of the eukaryotic translation initiation factor 4A family, plays a crucial role in mRNA translation and gene expression regulation. The protein is involved in the formation of the mRNA cap-binding complex and is essential for initiating translation by unwinding mRNA secondary structures, thus facilitating ribosome assembly. Research has revealed that EIF4A3 is not only pivotal in normal cellular functions but also linked to various diseases, including cancers, where its overexpression is often correlated with poor prognosis. Its role in alternative splicing, particularly as a component of the exon junction complex (EJC), underscores its importance in post-transcriptional regulation. Given its multifaceted roles and potential as a therapeutic target, understanding the molecular dynamics of EIF4A3, particularly through recombinant protein studies, is vital. These studies may elucidate its interactions with other cellular factors and reveal how alterations in EIF4A3 function contribute to disease mechanisms. Recombinant EIF4A3 proteins can be utilized in biochemical assays to assess binding affinities, enzymatic activities, and effects on translation processes, paving the way for potential clinical applications such as targeted therapies and diagnostics in cancer and other related disorders.
